Poorly differentiated neuroendocrine carcinoma of the small intestine is a rare, fast-growing cancer. It starts from cells in the lining of the small intestine that have features of neuroendocrine cells, which are cells that make hormones. This cancer can start anywhere in the small intestine, including the duodenum, jejunum, and ileum. It can also start in the ampulla, where the bile duct and pancreatic duct drain into the duodenum. Your report may call it a neuroendocrine carcinoma, NEC, small cell neuroendocrine carcinoma, or large cell neuroendocrine carcinoma.
This cancer is not the same as a well-differentiated neuroendocrine tumor, which is much more common and usually grows slowly. This article explains how doctors diagnose and stage poorly differentiated neuroendocrine carcinoma of the small intestine, and what the other findings in your pathology report mean.
Poorly differentiated neuroendocrine carcinoma of the small intestine is uncommon. Most neuroendocrine growths in the small intestine are well-differentiated neuroendocrine tumors, and only a small number are carcinomas. This cancer is found mostly in adults. Because it is so rare, reliable figures for age and sex for this site alone are limited.
The cause of poorly differentiated neuroendocrine carcinoma of the small intestine is usually not known. The cancer cells carry changes, called mutations, in genes that normally control cell growth. The most common change is in the gene TP53, which normally acts as a brake on cell division. Loss of another brake gene, RB1, is also frequent.
Some of these cancers develop next to an adenocarcinoma or a precancerous growth called an adenoma. This suggests that, in some people, the cancer starts from cells that first formed a glandular growth. A small number of these cancers are linked to an inherited condition called Lynch syndrome (see the biomarker section below).
The symptoms of poorly differentiated neuroendocrine carcinoma of the small intestine depend on where the tumor starts and how far it has spread. Most people are diagnosed after the cancer has already spread. Symptoms can include the following.
The diagnosis of poorly differentiated neuroendocrine carcinoma of the small intestine is made when a pathologist examines tissue from the tumor under a microscope. Tumors in the duodenum and ampulla are usually sampled with a biopsy during an upper endoscopy, in which a thin camera is passed through the mouth into the duodenum. Tumors in the jejunum and ileum are harder to reach, so the diagnosis is often made after surgery or from a needle biopsy of a tumor in the liver.
Under the microscope, the cancer cells grow in solid sheets and nests and divide very quickly. Large areas of dead tumor, called necrosis, are common. The pathologist uses special tests to confirm that the cells are neuroendocrine and to measure how fast they are dividing, as described in the next section.
Once the diagnosis is confirmed, imaging is used to find out how far the cancer has spread. This usually includes a CT scan of the chest, abdomen, and pelvis, and sometimes an MRI or a PET scan.
Pathologists use immunohistochemistry to confirm poorly differentiated neuroendocrine carcinoma of the small intestine. This test uses antibodies to show which proteins the cancer cells make. Your report may list the following results.
Not every case needs every stain. Your pathologist chooses the tests needed to answer the questions raised by your tumor.
The WHO classification of digestive system tumors (5th edition, 2019) divides this cancer into two types. The types are based on how the cells look under the microscope. Both types are treated similarly.
If the pathologist cannot tell which type is present, the report may say “neuroendocrine carcinoma (poorly differentiated)” without naming a type. Sometimes a neuroendocrine carcinoma is mixed with another type of cancer, such as adenocarcinoma. When each part makes up at least 30% of the tumor, the diagnosis is a mixed neuroendocrine-non-neuroendocrine neoplasm, or MiNEN. Your report will then describe each part of the tumor.
Poorly differentiated neuroendocrine carcinoma of the small intestine is a high-grade cancer by definition. Grade describes how different the cancer cells look from normal cells and how fast they divide. In this cancer, the pathologist sees more than 20 dividing cells (mitotic figures) in an area of 2 square millimeters, and the Ki-67 index is above 20%.
Because this cancer is always high grade, the grade does not vary from one patient to another. Some reports do not list a separate grade. Others list it as G3, or as G4 for small cell neuroendocrine carcinoma, using the CAP protocol categories. The high grade helps predict how the cancer will behave and guides treatment decisions, which are usually similar to those for small cell carcinoma of the lung.
Poorly differentiated neuroendocrine carcinoma of the small intestine starts in the inner lining and can grow deeper into the bowel wall. The pathologist describes how deep the cancer has grown, because this sets the tumor stage (pT). The wall of the small intestine has the following layers, from the inside out.
For tumors of the ampulla, the report also says whether the cancer has grown beyond the sphincter of Oddi, a ring of muscle around the ampulla. It also says whether the cancer has grown into the pancreas.
Perineural invasion means cancer cells are found along or around a nerve. In poorly differentiated neuroendocrine carcinoma of the small intestine, perineural invasion is reported as not identified, present, or cannot be determined. When present, it shows that the cancer can travel along nerves into nearby tissue.
Lymphovascular invasion means cancer cells are seen inside a blood vessel or a lymphatic channel. In poorly differentiated neuroendocrine carcinoma of the small intestine, lymphovascular invasion is reported as not identified, present, or cannot be determined. When present, it shows that cancer cells can spread to lymph nodes, the liver, and other organs.
When poorly differentiated neuroendocrine carcinoma of the small intestine is removed by surgery, the pathologist checks the margins. A margin is the cut edge of the tissue. The margins examined depend on the operation. For a segment of jejunum or ileum, they include the two cut ends of the bowel and the mesenteric margin. The mesenteric margin is the edge of the fatty tissue that holds the bowel in place. For a Whipple operation, they also include the bile duct, the pancreas, and the tissue next to the main blood vessels.
Lymph nodes are small immune organs that filter fluid from the bowel. Poorly differentiated neuroendocrine carcinoma of the small intestine often spreads to the lymph nodes in the mesentery or near the pancreas. During surgery, these lymph nodes are removed and examined under the microscope.
The report gives the total number of lymph nodes examined and how many contain cancer. The number of positive lymph nodes sets the nodal stage (pN). The report may also say whether there is extranodal extension. This means cancer cells have broken through the outer capsule of a lymph node into the surrounding tissue.
Biomarker testing in poorly differentiated neuroendocrine carcinoma of the small intestine looks for changes linked to specific treatments. It is most often done when the cancer is advanced or has spread. The ENETS 2023 guidance encourages molecular testing for these cancers. Most tumors will not have a change that leads to a targeted treatment, but a small number will.
Mismatch repair proteins fix mistakes that happen when a cell copies its DNA. The four proteins are MLH1, PMS2, MSH2, and MSH6. When one is lost, mistakes build up in the DNA, creating a pattern called microsatellite instability (MSI). About 4 in 100 high-grade neuroendocrine cancers of the digestive system are MSI-high.
Testing is done with immunohistochemistry for the four proteins, or with a DNA test for MSI. Results are reported as follows.
A deficient or MSI-high result matters for two reasons. First, pembrolizumab, an immunotherapy drug, is approved by the FDA (2017) and Health Canada for unresectable or metastatic MMR-deficient or MSI-high solid tumors that have grown after earlier treatment. Second, the result may point to Lynch syndrome, an inherited condition that raises the risk of several cancers. When MLH1 and PMS2 are lost, testing for MLH1 promoter methylation can help show whether the change is inherited. Genetic counseling may be offered.
BRAF is a gene that helps control cell growth. A specific change called V600E keeps the growth signal switched on. This change is found in a small number of neuroendocrine carcinomas of the digestive system. The test is usually done by DNA sequencing.
An NTRK gene fusion happens when part of an NTRK gene joins with another gene, creating a protein that drives growth. These fusions are very rare in this cancer. They are found by DNA or RNA sequencing.
Tumor mutational burden is the number of gene changes in the cancer cells, measured in mutations per megabase (mut/Mb) by next-generation sequencing. In one large study, about 7 in 100 high-grade neuroendocrine cancers of the digestive system were TMB-high.
Learn more about these tests in our Biomarkers section.
Poorly differentiated neuroendocrine carcinoma of the small intestine is staged using the AJCC Cancer Staging Manual, 8th edition, as used in current CAP protocols. The stage combines the tumor stage (pT) and nodal stage (pN). The metastatic stage (M) describes spread to distant organs and is usually determined by imaging rather than by the pathologist. The pT and pN categories differ for the ampulla, so both sets are given below.
Cancer in lymph nodes farther away, such as those near the aorta, is counted as distant spread (M1) rather than as nodal disease.
The prognosis for poorly differentiated neuroendocrine carcinoma of the small intestine is generally poor, because the cancer grows quickly and is usually found after it has spread. According to the ENETS 2023 guidance, the median survival for people with neuroendocrine carcinoma of the digestive system that has spread is 11 to 12 months. This means half of patients live longer than that, and half do not.
The outlook is better when the cancer is found before it has spread. Some people whose cancer is completely removed by surgery are cured. However, the cancer often comes back after surgery, so follow-up is close. Pathologic features associated with a worse outcome include the following.
A small group of MSI-high neuroendocrine carcinomas of the digestive system appears to have a better outlook than expected.
After poorly differentiated neuroendocrine carcinoma of the small intestine is confirmed, the next steps depend on how far the cancer has spread. Imaging and the stage, margins, and lymph nodes in the pathology report show this. A team that includes a medical oncologist, a surgeon, a gastroenterologist, and a radiation oncologist usually plans care.
If the biomarker tests suggest Lynch syndrome, you may be referred for genetic counseling, which can also help your family members.